The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 5.17% | 19.28% | 18.96% | 12.79% | N/A | 12.07% |
| Category returns | -2.99% | -4.52% | -3.02% | -5.03% | -4.77% | -2.03% | 9% | 10.98% | 7.45% | 11.5% | N/A |
| Absolute returns | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 10.62% | 69.77% | 100.38% | 82.58% | N/A | 82.76% |
| Rank within category | 154/268 | 16/252 | 1/241 | 3/228 | 3/207 | 12/162 | 2/134 | 9/112 | 8/81 | N/A | N/A |
| ETFs | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -10.86% | 34.44% | 39.59% | -2.46% | 13.16% |
| Q1 returns | N/A | -4.27% | -4.37% | 13.01% | -9.56% | -2% |
| Q2 returns | N/A | -10.46% | 14.53% | 3.84% | 4.34% | 13.97% |
| Q3 returns | N/A | 7.1% | 12.5% | 18.32% | -2.37% | 4.57% |
| Q4 returns | -1.68% | -2.9% | 9.11% | 0.53% | 5.88% | -3.12% |
| Alpha | -0.0155927 |
| Beta | 0.9991 |
| Sharpe Ratio | 0.300278 |
| Sortino Ratio | 0.652211 |
| R-Squared | 0.9971 |
| Tracking Error | 0.0548 |
| Downside Risk | 16.6659 |
| Std. Deviation (Annualised) | 14.0009 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | -7.16% | -4.01% | 10.11% | 12.75% | 6.7% | 19.48% | N/A | N/A | 19.41% | 44.40 | 0.36 | 0.30 | Very High |
| Nippon India Nifty Pharma ETF Current | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 19.28% | 12.79% | N/A | 12.07% | 1,736.44 | 0.23 | 0.30 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | -3.37% | -6.03% | -9.38% | -9.5% | -0.01% | 18.7% | N/A | N/A | 26.28% | 146.61 | 0.43 | 0.20 | Very High |
| DSP Nifty PSU Bank ETF | -0.29% | -1.08% | -5.84% | -7.11% | 9.24% | 18.66% | N/A | N/A | 20.49% | 1,434.17 | 0.16 | 0.15 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | -0.32% | -1.15% | -6.01% | -7.33% | 8.91% | 18.53% | N/A | N/A | 26.2% | 118.61 | 0.41 | 0.15 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | -0.32% | -1.17% | -6.04% | -7.39% | 8.81% | 18.35% | 25.56% | 10.01% | 6.93% | 3,932.00 | 0.51 | 0.14 | Very High |
| Kotak Nifty PSU Bank ETF | -0.32% | -1.17% | -6.06% | -7.4% | 8.79% | 18.33% | 25.56% | 9.94% | 6.36% | 2,490.74 | 0.51 | 0.14 | Very High |
| Aditya Birla Sun Life Nifty Healthcare ETF | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 18.01% | 0% | N/A | 12.85% | 74.67 | 0.20 | 0.27 | Very High |
| ICICI Prudential Nifty Healthcare ETF | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 17.87% | 12.38% | N/A | 12.86% | 231.43 | 0.16 | 0.27 | Very High |
| CPSE Exchange Traded Scheme | -4.68% | -8.11% | -17.4% | -5.64% | -6.14% | 17.73% | 22.49% | 13.23% | 13.75% | 18,645.20 | 0.08 | 0.19 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 19.50% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.97% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.82% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.68% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.62% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.16% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.00% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.69% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.56% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.16% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.92% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.88% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.71% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.62% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.34% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.14% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.77% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.67% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.43% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.30% |
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 0.18% | |
| Cash Margin - CCIL | Cash & Cash Equivalents and Net Assets | 0.00% | |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.15% | |
| Total | 100.00% | ||
Jitendra Tolani is Exchange Traded Fund Manager at Nippon India Mutual Fund and is also responsible for ETF dealing desk. He is a Post-graduate from Bharti Vidyapeeth University, Pune. He has over 16 years of experience in Sales Trading in the Institution Equities. His previous stint was at Motilal Oswal Financial Services of a Sales Trader- Institution Equities.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
